Molecular Targets and Inhibitors from the Society for Melanoma Research 9th International Conference

Summary: <p>CME credits: 0.50 Valid until: 07/08/2014 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6757</p><p>Even though the significant research efforts over the past 40 years have enabled profound changes in the approach and management of patients with advanced melanoma, the prognosis for patients remains poor. The NCI and ACS report that over 75,000 new cases of malignant melanoma were diagnosed in the US in 2011, and over 9,000 patients died from the disease. Melanoma has the fastest-rising incidence of any cancer, with an increase in the US from 1 in 1,500 in 1935 to a rate of 1 in 58 in 2011. Thus the importance of new information coming from a better understanding of molecular targets and inhibitors.</p> <p><strong>Estimated time to complete activity:</strong> 30 minutes</p> <p><img src="../images/cmsimages/CME/project_oncology_257.jpg" border="0" alt="Project Oncology" title="Project Oncology" width="257" height="53"></p>